DOI: 10.1111/dth.14262
View full text
Sign up to set email alerts

Abstract: Systemic lupus erythematosus (SLE) is a severe autoimmune disease distinguished by heterogeneity in diverse clinical manifestations. B cell hyperactivity play an essential role in the production of pathogenic autoantibodies and antigen presentation to T cells. Therefore, B celltargeting therapies, including B cell-depleting therapies (rituximab and ocrelizumab), inhibition of B cell survival factors (belimumab and atacicept), and modulating the terminal maturation stage of B cells (bortezomib), have been trial…

Expand abstract